Sign in
Taking people in United StatesPhase 1/2

Tests GV20-0251 alone and with pembrolizumab in advanced solid tumors

Tests GV20-0251, alone or with pembrolizumab, in adults with advanced solid tumors.

Key facts

Who runs it
GV20 Therapeutics
Where
Boston, Denver, Detroit, Fairfax, Fort Myers, Houston, Indianapolis, Los Angeles, Nashville, New Haven, New York, and Portland, United StatesSee the 13 sites
Trial code
Registry title
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Status
Recruiting
Phase
Phase 1/2
People taking part
365 people, planned
Started
23 Mar 2023
Expected to end
5 Sept 2027
Type of study
Interventional, 4 groups
Treatments tested
  • GV20-0251
  • GV20-0251 and Pembrolizumab [KEYTRUDA®]
Record updated
13 February 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with an advanced solid tumor that has got worse and did not respond to, or could not be treated with, standard therapy.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Advanced solid tumor that has been treated before and is getting worse. It must be measurable on scans (RECIST 1.1). Some parts of the trial look for endometrial cancer, head and neck squamous cancer, skin melanoma, non-small cell lung cancer, or colon or rectal cancer (pMMR/MSS).
Earlier treatment
Must have had standard therapy, or not be able to take it, or have declined it. After a checkpoint inhibitor, the disease must be documented as getting worse. Other investigational drugs within 4 weeks and anticancer treatment within 2 weeks before the first dose are not allowed.
Biomarker or test result
Not stated, except that colon or rectal cancer must be pMMR/MSS.

Main reasons for not taking part

  • Heart disease or unstable heart rhythm problems
  • Active autoimmune disease or need for long-term steroids or immune-suppressing drugs
  • History of major organ transplant or bone marrow transplant
  • Symptomatic cancer in the brain or spinal cord
  • Pregnant or nursing women

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • Participants ≥18 years of age
  • Previously treated, histologically-confirmed advanced solid malignancy with progressive disease requiring therapy
  • Refractory or intolerant to standard therapy(ies)
  • Must have received, be not eligible or decline standard of care therapy
  • Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST version 1.1)
  • For participants who have received prior treatment with a checkpoint inhibitor there must be documented disease progression
  • ECOG performance status of 0 or 1
  • Life expectancy of ≥ 12 weeks in Parts A and C and ≥ 24 weeks in Parts B and D
  • Participants must be willing to provide fresh tumor biopsy (core biopsy) both pre-treatment (Parts A, B, C and D) and on-treatment (Parts A and B), if clinically feasible
  • Disease-free of active second/secondary or prior malignancies for ≥ 2 years
  • Laboratory test results within the required parameters
  • Women of child bearing potential (WOCBP) and men must agree to use adequate contraception
  • Parts B, C and D may include the following tumor types:; Endometrial carcinoma; Squamous head and neck carcinoma; Cutaneous melanoma; Non-small cell lung cancer; Proficient MMR (pMMR)/MSS adenocarcinoma of the colon or rectum (Parts C and D only); Parts A, B, C and D Exclusion Criteria:
  • Participant with acute leukemia or CLL (Parts A and B only)
  • Participant with heart disease or unstable arrhythmia
  • Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy
  • Participant has active autoimmune disease or other medical conditions requiring chronic systemic steroid or immunosuppressive therapy
  • History of major organ transplant
  • History of a bone marrow transplant
  • Symptomatic central nervous system (CNS) malignancy or metastasis
  • Serious nonmalignant disease
  • Pregnant or nursing women
  • Treatment with PD-1 and equivalent immune modulators or major surgery prior to the first dose of study medication
  • Participants who are currently receiving any other investigational agent or have received an investigational agent within 4 weeks prior to the first dose of study medication
  • Treatment with any anticancer treatments with 2-weeks prior to the first dose of study medication
  • Radiation for symptomatic lesions must have been completed prior to the first dose of study medication
  • Participants with liver metastases unless approved by the Sponsor
  • Any history of an immune related ≥ Grade 3 AE attributed to prior cancer immunotherapy
  • Has a known additional malignancy that is progressing or has required active treatment within the past 2 years from C1D1
  • Has received radiation therapy to the lung that is higher than 30 Gy within 6 months prior to C1D1 for NSCLC (Parts C and D only)
  • Has a known additional malignancy that is progressing or has required active treatment within the past 2 years from C1D1 (Parts C and D only)
  • Has severe hypersensitivity ( ≥ Grade 3) to Pembrolizumab and/or any of its excipients (Parts C and D only)
  • Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease (Parts C and D only)
  • Has a condition, therapy, laboratory abnormality, or circumstance that could confound study results or interfere with full participation, making it unsuitable for the participant, as determined by the treating Investigator (Parts C and D only)
  • Active substance abuse

Where in United States

  • Massachusetts General HospitalBoston, United StatesContact: GV20 TherapeuticsTaking people
  • HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONEDenver, United StatesContact: GV20 TherapeuticsNot yet recruiting
  • Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer CenterDetroit, United StatesContact: GV20 TherapeuticsTaking people
  • Virginia Cancer SpecialistsFairfax, United StatesContact: GV20 TherapeuticsTaking people
  • Florida Cancer Specialists & Research Institute, LLCFort Myers, United StatesContact: GV20 TherapeuticsNot yet recruiting
  • Oncology Consultants, P.A.Houston, United StatesContact: GV20 TherapeuticsTaking people
  • The University of Texas M. D. Anderson Cancer CenterHouston, United StatesContact: GV20 TherapeuticsTaking people
  • Community Health Network, IncIndianapolis, United StatesContact: GV20 TherapeuticsTaking people
  • The Angeles Clinic and Research InstituteLos Angeles, United StatesContact: GV20 TherapeuticsTaking people
  • Verdi Oncology Tennessee, Scri Oncology PartnersNashville, United StatesContact: GV20 TherapeuticsNot yet recruiting
  • Yale UniversityNew Haven, United StatesContact: GV20 TherapeuticsTaking people
  • NYU Langone HealthNew York, United StatesContact: GV20 TherapeuticsTaking people
  • Oregon Health Science UniversityPortland, United StatesContact: GV20 TherapeuticsTaking people

About the trial

What the trial wants to find out

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

The 4 groups in the trial

  • Part A - Dose Escalation in up to 7 dose levelsTreatment being tested

    A 3+3 dose escalation scheme will be used to evaluate the safety and tolerability of GV20-0251, and to establish the maximum tolerated dose (MTD) or the preliminary recommended Phase 2 dose (RP2D).

    Treatment: GV20-0251

  • Part B - Multiple Expansion Cohorts in up to 4 tumor indicationsTreatment being tested

    The Bayesian optimal design for Phase II (BOP2) will be utilized to further characterize the anti-tumor activities, safety, tolerability, pharmacokinetics, and pharmacodynamics of GV20-0251 at the preliminary RP2D in up to 4 expansion cohorts involving eligible participants.

    Treatment: GV20-0251

  • Part C - GV20-0251 in Combination with Pembrolizumab Dose Escalation in 2-4 dose levelsTreatment being tested

    The Bayesian optimal interval (BOIN) design will be employed to evaluate the safety and tolerability of GV20-0251 in combination with pembrolizumab, and to determine the MTD or the preliminary RP2D of this combination in selected tumor indications.

    Treatment: GV20-0251 and Pembrolizumab [KEYTRUDA®]

  • Part D - GV20-0251 in Combination with Pembrolizumab Dose Expansion in up to 5 indicationsTreatment being tested

    The BOP2 will be applied to further characterize the anti-tumor activities, safety, tolerability, pharmacokinetics, and pharmacodynamics of GV20-0251 in combination with pembrolizumab at the preliminary RP2D in up to 5 expansion cohorts involving eligible participants.

    Treatment: GV20-0251 and Pembrolizumab [KEYTRUDA®]

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies
Plain-language title
Tests GV20-0251 alone and with pembrolizumab in advanced solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 February 2025